Suzetrigine, approved by the FDA, marks a significant advancement in pain management as it uniquely targets peripheral nerves to alleviate pain, distinguishing it from traditional opioids, who pose addiction risks. Its effectiveness in managing moderate to severe pain, particularly post-surgery, was validated through clinical trials, suggesting it could serve as a safer alternative. Vertex Pharmaceuticals aims to provide relief for millions affected by acute pain without common opioid side effects. Experts view this approval as a breakthrough in pain treatment options, emphasizing its potential in changing pain management paradigms.
"Today's approval is a historic milestone for the 80 million people in America who are prescribed a medicine for moderate-to-severe acute pain each year," Reshma Kewalramani, CEO and president of Vertex, said in a statement.
Suzetrigine is not intended to replace opioid medications in their entirety. Rather it can offer a relatively (relative to opioids) risk-free way of managing pain acutely," said Bannister.
Collection
[
|
...
]